Drug Profile

Glesatinib companion diagnostic - Guardant Health/Mirati Therapeutics

Alternative Names: MGCD-265 companion diagnostic

Latest Information Update: 25 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

No development reported Head and neck cancer; Non-small cell lung cancer; Solid tumours

23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer(Diagnosis) in USA
04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com